Clinical trials: Systemic Sclerosis, Diffuse
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Diet Habit, Rheumatologic Disease
Rheumatology Diet Study
This study aims to collect information on rheumatology patients' dietary habits, autoimmune disease activity, dietary changes, disease symptom improvements, and perceptions on their dietary habits and how it affects their…
- Conditions
- Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis
- Trial name
- NCT06339957
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Central Florida
Scleroderma, Systemic
Development and Evaluation of an Evidence-based Education Program for People With Hand Dysfunction in Scleroderma
The purpose of this study is to develop an evidence-based educational program for scleroderma patients with hand dysfunction. The program includes a self-care handbook and multimedia video resources.
- Trial name
- NCT06697561
- Testing
- patient education program
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Wen-Shao Lin
Interstitial Lung Disease, Scleroderma
Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease
Interstitial lung disease (ILD) is a diverse group of parenchymal lung disorders characterized by restrictive lung function and impaired alveolar diffusion capacity, leading to dyspnea on exertion, reduced exercise endurance, and…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT03560154
- Testing
- Whole Body Vibration Training
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul University
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Scleroderma, Systemic Sclerosis
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies.
- Trial name
- PSSIT (NCT05098704)
- Testing
- clopidogrel treatment
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Bordeaux
Systemic Sclerosis, Scleroderma
Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Systemic sclerosis is a chronic autoimmune connective tissue disorder with no universally accepted disease modifying regimen. Recruiting patients for systemic sclerosis treatment studies is difficult due to the limited…
- Trial name
- NCT01093885
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pennsylvania
Scleroderma Systemic
Periodontal Microbiota in Systemic Sclerosis
Systemic sclerosis (SSc) is a rare and complex autoimmune disease. Although its etiology remains unknown, various environmental factors, including certain microorganisms, can represent potential triggers of SSc in individuals…
- Trial name
- Periomicross (NCT06182293)
- Testing
- Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Sclerosis
Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Primary Objective: To evaluate, in comparison with placebo, the efficacy of SAR156597 administered subcutaneously for 24 weeks on skin fibrosis in participants with diffuse cutaneous systemic sclerosis (dcSSc).
- Trial name
- NCT02921971
- Testing
- SAR156597
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 97 people
- Sponsor
- Sanofi
Scleroderma, Diffuse, Scleroderma, Systemic
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease that involves the skin and other internal organs for which there are few effective treatment options.
- Trial name
- NCT00442611
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Scleroderma
Premature Coronary Atherosclerosis in Scleroderma
The purpose of this trial is to study the proportion of scleroderma patients who suffer from asymptomatic coronary atherosclerosis compared to healthy controls.
- Trial name
- NCT00372398
- Where
- Hong Kong
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Tuen Mun Hospital
Systemic Scleroderma, Pulmonary Hypertension
Placebo Controlled Trial of Bosentan in Scleroderma Patients
The purpose of this study is to determine whether the drug Bosentan improves exercise tolerance in scleroderma patients.
- Trial name
- NCT00377455
- Testing
- Bosentan
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Georgetown University
Systemic Sclerosis, Fibromyalgia
Effects of Fibromyalgia Syndrome in Patients With Systemic Sclerosis
Systemic sclerosis [SSc]; is a multisystem disease characterized by immune activation, microvascular disease and fibroblast dysfunction, which is thought to occur as a result of complex and not fully understood interaction…
- Trial name
- NCT04411498
- Testing
- Fibromyalgia diagnosis in patients with SSc
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Systemic Sclerosis, Raynaud Phenomenon
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it to the standard of care treatment (intravenous…
- Conditions
- Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer, Scleroderma
- Trial name
- RHEACT (NCT05204784)
- Testing
- Rheopheresis treatment, Intravenous Infusion
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Peter Korsten
Scleroderma, Diffuse
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis…
- Trial name
- NCT06655896
- Testing
- rapcabtagene autoleucel, rituximab
- Where
- 93 sites in United States, Argentina and 20 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Scleroderma, Systemic Sclerosis
Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study
The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma from Canada, the USA, and Europe.
- Trial name
- SPIN-HAND-F (NCT03092024)
- Testing
- SPIN-HAND program
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Lady Davis Institute
Lupus Erythematosus, Systemic, System; Sclerosis
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
The CATARSIS study explores the use of anti-CD19 CAR T-cell therapy as a novel approach for treating refractory systemic autoimmune diseases, specifically SLE, SSc, DM/PM, and AAV.
- Conditions
- Lupus Erythematosus, Systemic, System; Sclerosis, ANCA Associated Vasculitis, Dermatomyositis
- Trial name
- CATARSIS (NCT06685042)
- Testing
- CAR T cell
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Scleroderma
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.
- Trial name
- MEDI-546 (NCT00930683)
- Testing
- MEDI-546
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- MedImmune LLC
Systemic Sclerosis
MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis
To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of…
- Trial name
- SCLERAMAC (NCT04244916)
- Testing
- AUC of MPA measure
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Diseases, Interstitial, Systemic Sclerosis
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
- Conditions
- Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
- Trial name
- NCT02370693
- Testing
- Bortezomib, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University